Bisacodyl

Banu A, et al. Journal of Molecular Liquids, 2023, 387, 122488.

This study demonstrates the formulation of bisacodyl (BSL)-loaded chitosan nanoparticles (BSL@CS NPs) using a modified ionotropic gelation technique. Chitosan (CS) and bisacodyl were dissolved in 1% (v/v) acetic acid to ensure polymer solubilization and homogeneous drug dispersion. The pH was carefully adjusted with NaOH to optimize electrostatic interaction between the protonated amine groups of CS and the crosslinker. Subsequently, aqueous sodium tripolyphosphate (TPP) was added dropwise under magnetic stirring at room temperature, inducing ionic crosslinking and spontaneous nanoparticle formation. This method highlights Bisacodyl's experimental application in controlled drug delivery systems, demonstrating its compatibility with polysaccharide-based nanocarriers and its suitability for nanoparticulate formulation development.

Tuncal A, et al. Clinica Chimica Acta, 2024, 558, 118992.

This study evaluates bisacodyl as a candidate therapeutic compound targeting CHEK2-associated pathways in chondrosarcoma (CS). Using an in silico Drug Set Enrichment Analysis (DSEA) approach through the Gene2Drug platform, compounds were screened for gene-specific modulation. CHEK2, implicated in cell cycle regulation and cancer susceptibility, was selected as a potential therapeutic target based on genomic analyses of dedifferentiated CS.
Drug sensitivity profiling was conducted using PRISM Repurposing Primary data across eight CS cell lines. Among 593 screened agents, eight compounds demonstrated significant sensitivity (P < 1×10⁻³), with bisacodyl identified as a promising candidate. Mechanistically, bisacodyl is associated with G protein-coupled receptor 35 modulation, a class widely investigated in oncology. This study highlights bisacodyl's experimental application in computational drug repurposing pipelines combined with large-scale viability assays, supporting its potential utility in precision-targeted therapy for chondrosarcoma.